eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Cancer
- Woman & Child Health & Rare Diseases
Team
Group Leader
Ibane Abasolo Olaortua, Roser Ferrer Costa
Principal Investigator (PI)
Simó Schwartz Navarro, Joaquin Seras Franzoso, Francisco Rodríguez Frias, Rosanna Paciucci Barzanti, Diana Fernandes da Sousa Rafael
Researchers
Fernanda Raquel Da Silva Andrade, Zamira Vanessa Diaz Riascos, José Antonio Arranz Amo, Laura Conesa Milian, Joan López Hellin, Albert Blanco Grau, Clara Carnicer Cáceres, Jaume Vima Bofarull, Luisa Maria Martinez Sánchez, Fernando Moreno Flores, Joaquin Ruiz Altarejo, Pilar Reimundo Díaz-Fierros, Andrea Caballero Garralda, Imma Comas Reixach, Mª Pilar Felipe Fernandez
PhD Students
Diego Baranda Martínez-Abascal, Marc Miquel Moltó Abad, Clara Ramírez Serra, Yolanda Villena Ortiz, Pablo Gabriel Medina, Mª Teresa Gené Juyent,Verónica Villagrasa Araya, Maria Fidel Lledò, Daniel Bravo Nieto, Gonzalo González Silva, Alba Estela García Fernández, Sarai Garriga Edo, Andrea Arias Garcia, Laura Castellote Bellés, Laura Castillo Ribelles, Marina Giralt Arnaiz, Noelia Díaz Troyano,
Lab Technicians
Angels Alcina Mila, Laura García Latorre, Pilar Bonet Palomares, Sandra Mancilla Zamora, Belen Garcia Prats, Francisco Jesus Torralba Saban, Julia German Cortes
Nursing and Technical Staff
Maria del Carmen Sanchez Valcarcel, Mireia Benito Jimenez,
Selected Publications
Patricia González-Callejo, Clara García-Astrain, Ada Herrero-Ruiz, Malou Henriksen-Lacey, Joaquín Seras-Franzoso, Ibane Abasolo, Luis M. Liz-Marzán
3D Bioprinted Tumor-Stroma Models of Triple-Negative Breast Cancer Stem Cells for Preclinical Targeted Therapy Evaluation.
ACS Appl. Mater. Interfaces 2024, 16, 21, 27151–27163
DOI: 10.1021/acsami.4c04135
IF: 8.5
Judit Tomsen-Melero, Marc Moltó-Abad, Josep Merlo-Mas , Zamira V. Díaz-Riascos , Edgar Cristóbal-Lecina , Andreu Soldevila, Thomas Altendorfer-Kroath , Dganit Danino, Inbal Ionita , Jan Skov Pedersen, Lyndsey Snelling, Hazel Clay, Aida Carreño, José L. Corchero, Daniel Pulido, Josefina Casas, Jaume Veciana, Simó Schwartz Jr., Santi Sala, Albert Font, Thomas Birngruber, Miriam Royo, Alba Córdoba , Nora Ventosa, Ibane Abasolo and Elisabet González-Mira.
Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease
Sci Adv. 2024 Dec 13;10(50):eadq4738.
DOI: 10.1126/sciadv.adq4738
IF: 13.9
Dopeso H, Rodrigues P, Cartón-García F, Macaya I, Bilic J, Anguita E, Jing L, Brotons B, Vivancos N, Beà L, Sánchez-Martín M, Landolfi S, Hernandez-Losa J, Ramon Y Cajal S, Nieto R, Vicario M, Farre R, Schwartz S Jr, van Ijzendoorn SCD, Kobayashi K, Martinez-Barriocanal Á, Arango D.
RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis.
iScience. 2024 Mar 1;27(4):109400
DOI: 10.1016/j.isci.2024.10940
IF: 5.8
Laura Castillo-RibellesJose Antonio Arranz-AmoJorge Hernández-VaraDaniela Samaniego-ToroSilvia Enriquez-CalzadaSara Lucas-Del PozoMaria Camprodon-GomezAriadna LagunaMercedes Arrúe GonzaloRoser FerrerMarta Martinez-VicenteClara Carnicer-Caceres*
Evaluation of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Analysis of Glucosylceramide and Galactosylceramide Isoforms in Cerebrospinal Fluid of Parkinson's Disease Patients
Anal Chem. 2024 Jul 24.
DOI: 10.1021/acs.analchem.4c02654
IF: 6.8
Carmen Llorens-Cebrià, Norberto Núñez-Seral, Yolanda Villena-Ortiz, Irene Martínez-Díaz, Maria José Soler, Roser Ferrer-Costa*, Conxita Jacobs-Cachá*, Joan López-Hellín.
Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS).
J Am Soc Mass Spectrom. 2024 Sep 20
DOI: 10.1021/jasms.4c00155
IF: 3.1
Selected Projects
Engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small Cell Lung Cancer (MycoMatrix)
Principal Investigator: Fernanda Raquel da Silva Andrade
Agency: MICINN – Program RETOS.
Funding: 1,481,192.60 € (Total); 333,700€ (to CB-DDT group at VHIR).
Period: 2024-2026
A KEY TO THE RATIONAL DESIGN OF EXTRACELLULAR VESICLES-MIMICKING NANOPARTICLES (MIMIC-KeY)
Principal Investigator: Simo Schwartz Jr
Agency: EC/H2020/ FETPROACT/2020/SCHWARTZ_MIMIC-KEY
Funding: (2,902,527€ for 7 partners); 457,250,00 euros to the group.
Period: 2021-2025
Biodegradable and Eco-friendly Smart Hydrogels for the Sustained Intraperitoneal Release of Chemotherapeutics as a Novel Local Therapy Approach for Advanced Ovarian Cancer (HYDROTECH)
Principal Investigator: Simo Schwartz Jr and Diana Rafael Fernandes
Agency: European Commission – HORIZON-MSCA-2022-PF-01 - HORIZON
Funding: 221,390.88 €
Period: 2023-2024
Autonomous Scanning Probe Microscopy for Life Sciences and Medicine powered by Artificial Intelligence (SPM4.0)
Principal Investigator: Fernanda Raquel Andrade
Agency: European Commission – HORIZON-MSCA-2023-DN-01
Funding: (3,942,360.00 € for 22 partners); 251,971.20 € to the group.
Period: 2024-2026
Patient-Centric blOod saMpling FOr impRoved healThcare (COMFORT)
Principal Investigator: Simo Schwartz Jr
Agency: European Commission – HORIZON-JU-IHI-2023-04-two-stage
Funding: Amount: 8,464,028.75€ for 53 partners; 288,262.5 € to the group
Period: 2024-2028
Role of Apolipoprotein A-Ib in the idiopathic nephrotic syndrome
Principal Investigator: Conxita Jacobs Cachá
Agency: Fundació La Marató de TV3
Funding: 199,966 €
Period: 2021-2024
Patents
Biomarkers for bioimplants risk of bad response.
Priority Number: PCT/EP2011/056393
Priority Date: 2010
Applicants: 100% VHIR
Functionalized Liposomes Useful For The Delivery Of Bioactive Compounds
Priority Number: PCT/EP2013/063646
Priority Date: 28/06/2013
Applicants: CSIC, CIBER, VHIR
Cell Penetrating Peptides
Priority Number: P5615EP00
Priority Date: 2020
Applicants: 100% VHIR
Liposomes and its use for Enzyme Delivery
Priority Number: EP21382062.4
Priority Date: 27/01/2021
Applicants: CSIC, VHIR, UAB, NANOMOL TECHNOLOGIES SL, LEANBIO SL
Methods to Produce Enzymes
Priority Number: P4886ES00
Priority Date: 24/01/2019
Applicants: VHIR, CIBER
Selected Dissemination Activities
VHIR participates in the study of a new therapy that opens the way in the treatment of Fabry disease
Place: VHIR online
Date: 01/01/1970
Brief: An international research team led by researcher Nora Ventosa from the Nanomol-Bio group of ICMAB-CSIC and CIBER-BBN has developed a new nanotechnology-based therapy called nanoGLA for the treatment of Fabry disease. The new therapeutic solution has demonstrated remarkable efficacy in preclinical studies. The study, which was carried out in collaboration with the Vall d’Hebron Research Institute (VHIR), was published this December in the open access journal Science Advances.
MORE INFO
VHIR participates in the EU Project SPM4.0
Place: Barcelona
Date: 12/10/2024
Brief: Researchers from across Europe gathered for the kick-off meeting of the SPM4.0 project, an innovative Marie Curie Skłodowska Doctoral Network (MSCA-DN) dedicated to advancing the capabilities of autonomous Scanning Probe Microscopy (SPM) powered by Artificial Intelligence. The event, marked the beginning of a forward-thinking initiative aimed at training a new generation of researchers to push the boundaries of technology within the Life Sciences and Medical fields.
MORE INFO
Science week fair
Place: Barcelona
Date: 11/12/2024
Brief: We showcased a visit to the biochemistry labs at Vall d'Hebron, joined several activities related to the use of nanosystems in our research laboratories and finally share the results of a Marato TV3 project funded in 2019 and lead by our PI Dr Conxita Jacobs, on the Apolipoprotein A-Ib (ApoA-Ib).
MORE INFO
Europe's Night
Place: Barcelona
Date: 01/01/1970
Brief: A science dissemination fair with public activities
MORE INFO
Fundació Marató TV3 visit
Place: Barcelona - VHIR
Date: 03/05/2024
Brief: visit from Marató TV3 Fundation at VHIR after ending the project funded by Marato TV3 2019 focused in a protein that improves the diagnosis and treatment of idiopathic nephrotic syndrome, a rare kidney disease.
MORE INFO
